Lanean...
Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma
BACKGROUND: The introduction of rituximab into the treatment of patients with non-Hodgkin’s lymphomas has improved the overall response rate, as well as the response duration and the overall survival of patients with B-cell lymphomas. But only a few studies have addressed the question whether the be...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Versita, Warsaw
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3423703/ https://ncbi.nlm.nih.gov/pubmed/22933921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/v10019-010-0044-6 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|